ScoreWhy is Nephros, Inc. ?
1
With a growth in Net Sales of 5.5%, the company declared Very Positive results in Sep 25
- The company has declared positive results for the last 3 consecutive quarters
- NET PROFIT(HY) At USD 0.57 MM has Grown at 641.51%
- OPERATING CASH FLOW(Y) Highest at USD 2.71 MM
- NET SALES(HY) At USD 9.18 MM has Grown at 35.64%
2
With ROE of 14.80%, it has a very attractive valuation with a 3.11 Price to Book Value
- Over the past year, while the stock has generated a return of 96.10%, its profits have risen by 241% ; the PEG ratio of the company is 0.1
3
High Institutional Holdings at 50.63%
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
- Their stake has increased by 4.2% over the previous quarter.
4
Market Beating Performance
- The stock has generated a return of 96.10% in the last 1 year, much higher than market (S&P 500) returns of 13.68%
Real-Time Research ReportHow much should you buy?
- Overall Portfolio exposure to Nephros, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Nephros, Inc. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Nephros, Inc.
96.1%
0.37
102.43%
S&P 500
13.5%
0.71
19.28%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
13.81%
EBIT Growth (5y)
18.65%
EBIT to Interest (avg)
-2.78
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.40
Sales to Capital Employed (avg)
1.60
Tax Ratio
1.50%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
50.63%
ROCE (avg)
2.77%
ROE (avg)
1.72%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
21
Industry P/E
Price to Book Value
3.11
EV to EBIT
18.19
EV to EBITDA
16.53
EV to Capital Employed
5.04
EV to Sales
1.47
PEG Ratio
0.08
Dividend Yield
NA
ROCE (Latest)
27.71%
ROE (Latest)
14.80%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bullish
Moving Averages
Bearish (Daily)
KST
Bearish
Bullish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
Mildly Bearish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend19What is working for the Company
NET PROFIT(HY)
At USD 0.57 MM has Grown at 641.51%
OPERATING CASH FLOW(Y)
Highest at USD 2.71 MM
NET SALES(HY)
At USD 9.18 MM has Grown at 35.64%
ROCE(HY)
Highest at 16.29%
RAW MATERIAL COST(Y)
Fallen by -0.59% (YoY
0What is not working for the Company
NO KEY NEGATIVE TRIGGERS
Here's what is working for Nephros, Inc.
Net Profit
At USD 0.57 MM has Grown at 641.51%
Year on Year (YoY)MOJO Watch
Net Profit trend is very positive
Net Profit (USD MM)
Net Sales
At USD 9.18 MM has Grown at 35.64%
Year on Year (YoY)MOJO Watch
Near term sales trend is positive
Net Sales (USD MM)
Operating Cash Flow
Highest at USD 2.71 MM
in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (USD MM)
Raw Material Cost
Fallen by -0.59% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
